First new CANTAB® product features developed & launched from the landmark INTUITION project
Cambridge Cognition (AIM: COG), the neuroscience technology company, announces two new product features for its CANTAB digital cognitive assessments derived from analysis of data from the INTUITION project.
- Application of Expanded Normative Dataset – Increased Sensitivity and Accuracy of CANTAB®
The first development is an expanded normative dataset derived from Project INTUITION to support improved sensitivity and accuracy over earlier releases. Normative data provides the reference information against which an individual’s cognitive performance is measured. The comparison matches an individual to their appropriate comparator group within the dataset taking into account that person’s age, biological sex and level of education. These updates are being deployed across the digital touchscreen cognitive assessments which are core to CANTAB Pathway™ and used in both clinical studies and academic research.
- Automatic detection of inattention
The unique scale and structure of the Intuition dataset has enabled Cambridge Cognition to develop a proprietary machine learning algorithm to distinguish when a user has been distracted while taking a task. This functionality has been deployed into the Company’s CANTAB One solution. When the algorithm detects that an individual has been distracted, the assessment will be flagged and can prompt the individual to retake the task. This feature is intended to reduce false positive detection of cognitive impairment by automatically screening out inattention scores, improving accuracy. It is expected that this feature will be rolled out into live field trials in the coming weeks. Following these trials, the Company intends to deploy this improvement across all uses of CANTAB One.
INTUITION Brain Health Study
The INTUITION Brain Health Study commenced in September 2021, and after 18-months on 13 March 2023, achieved its overall planned enrolment goal of 23,000 adults across the United States.
In total the study collected cognitive assessment data from these 23,000 participants completing 2-4 tasks at each timepoint, generating more than 3.2 million sessions. Consequently, the analysis is powered by over 7 million total completed tasks. The study used iPhone and Apple Watch technology to remotely collect cognitive and behavioural data over time. Cambridge Cognition’s CANTAB® assessments provided all cognitive data assessments and were central to the study. The tasks measured memory, attention and executive function across all subjects without clinical supervision.
The initial findings from project INTUITION were published on 4 March 2025 in Nature Medicine: (https://pmc.ncbi.nlm.nih.gov/articles/PMC11922773). The study is recorded at Clinicaltrials.gov at: https://clinicaltrials.gov/study/NCT05058950. Owing to its size, the Company believes this to be one of the world’s leading datasets in the field.
Application of improvements and future developments
Both new developments announced can be applied to CANTAB generally for use in all four segments: academic research, clinical studies, healthcare and consumer health and wellness.
Cambridge Cognition has identified important applications, using outputs from the INTUITION project, in clinical trial recruitment to assist sponsors seeking to identify candidates remotely who have a cognitive function profile matching the selection criteria for their clinical trials.
The analysis of the dataset continues, and Cambridge Cognition expects to release multiple further product features and capabilities. The dataset’s applications extend well beyond its observational study origins, providing a foundation for expansion into new therapeutic areas across all market segments.
Advances which are currently in development include:
- new scoring methods that increase the statistical power of existing tests while remaining fully backward compatible with previous studies
- shorter adaptive test versions that reduce completion time
- richer metrics for tracking how cognition changes over time
Further findings from this work were presented at ISCTM Conference (isctm.org) on 16th September 2026 in Philadelphia, PA, USA.
Rob Baker, Chief Executive Officer of Cambridge Cognition, said:
“What we’ve built from the INTUITION study is a significant proprietary dataset that no competitor can easily replicate, and which gets more valuable with every analysis we run.
We are using the data to make our tests more powerful, faster to complete, and better at tracking how cognition changes over time — all while ensuring existing clients benefit immediately without changing their protocols. None of this would be possible without data at this scale.
Today’s announcements are the first new product releases from this programme. We expect more to follow as we continue to unlock new capabilities from this unique asset. These new developments demonstrate the significant value that can be unlocked through the major multi-year collaborations which we engage in.”
